Sonuga BO, Hellenberg DA, Cupido CS, Jaeger C, Hospital V, Sonuga BO. Profile and anticoagulation outcomes of patients on warfarin therapy in an urban hospital in Cape Town, South Africa. African J Prim Heal care Fam Med. 2016;8(1):1–8.
Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315–52.
Tran NT, Lin CH, Do NN, Muradian IK, Lu QD, Henderson SO. The impact of implementing an advance practice pharmacist-led anticoagulation clinic within a correctional facility. J Pharm Pract. 2021;34(4):631–4.
Laäs DJ, Naidoo M. An evaluation of warfarin use at an urban district-level hospital in Kwazulu-natal Province, South Africa. S Afr Med J. 2018;108(12):1046–50.
Witt DM, Nieuwlaat R, Clark NP, Ansell J, Holbrook A, Skov J, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: Optimal management of anticoagulation therapy. Blood Adv. 2018;2(22):3257–91.
Article PubMed PubMed Central Google Scholar
Zeitler EP, Eapen ZJ. Anticoagulation in Heart Failure: a Review. J Atr Fibrillation. 2015;8(1):1250.
Minno A Di, Frigerio B, Spadarella G, Sansaro D, Amato M, Kitzmiller JP, et al. Old and new oral anticoagulants: Food, herbal medicines and drug interactions. 2017. Available from: https://doi.org/10.1016/j.blre.2017.02.001.
Karuri S, Nyamu D, Opanga S, Menge T. Factors associated with time in therapeutic range among patients on oral anticoagulation therapy in a tertiary teaching and referral hospital in Kenya. East Cent African J Pharm Sci. 2019;22(3):85–95.
Alghadeeer S, Alzahrani AA, Alalayet WY, Alkharashi AA, Alarifi MN. Anticoagulation control of warfarin in pharmacist-led clinics versus physician-led clinics: A prospective observational study. Risk Manag Healthc Policy. 2020;13:1175–9.
Article PubMed PubMed Central Google Scholar
Mwita JC, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, Magafu MGMDMD. Quality of anticoagulation with warfarin at a tertiary hospital in Botswana. Clin Appl Thromb. 2018;24(4):596–601.
Gabriel P, Barros M De, Sznejder H, Vasconcellos R, Charles GM, Tannus H, et al. Original Article anticoagulation therapy in patients with non-valvular atrial fibrillation in a private setting in Brazil : A Real ‑ World Study. 457–66.
Choumane NS, Malaeb DN, Malaeb B, Hallit S. A multicenter, prospective study evaluating the impact of the clinical pharmacist-physician counselling on warfarin therapy management in Lebanon. BMC Health Serv Res. 2018;18(1):1–7.
Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I, Roldán V, Muñiz J, Raña-Míguez P, et al. Quality of oral anticoagulation with Vitamin K antagonists in “real-world” patients with atrial fibrillation: A report from the prospective multicentre FANTASIIA registry. Europace. 2018;20(9):1435–41.
Turen S, Turen S. Determination of factors affecting time in therapeutic range in patients on warfarin therapy. Biol Res Nurs. 2023;25(1):170–8.
Article CAS PubMed Google Scholar
Ntlokotsi S, Moshesh MF, Mntla P, Towobola OA, Mogale MA. Optimum INR intensity and therapeutic INR control in patients with mechanical heart valve prosthesis on warfarin oral anticoagulation at Dr George Mukhari academic hospital: a three-year retrospective study. South African Fam Pract. 2018;60(6):192–6.
Krittayaphong R, Chantrarat T, Rojjarekampai R, Jittham P. Poor time in therapeutic range control is associated with adverse clinical outcomes in patients with non-valvular atrial fibrillation : a report from the Nationwide COOL-AF Registry. J Clin Med. 2020;9(6):1–13.
Vestergaard AS, Skj F, Larsen TB, Ehlers H. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation : A systematic review and meta-regression analysis. 2017. p. 1–17.
Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, et al. Evaluation of time in therapeutic range in anticoagulated patients: A single-center, retrospective, observational study. BMC Res Notes. 2014;7(1):1–5.
Gateman D, Trojnar ME, Agarwal G, Gateman D, Trojnar ME, Agarwal G. Time in therapeutic range Un RIN dans la fourchette thérapeutique. Canadian Family Phys. 2017;63:425–31.
Chan P, Li WH, Hai J, Chan EW, Wong ICK, Tse H, et al. Time in therapeutic range and percentage of INRs in therapeutic range as measure of quality of anticoagulation control in atrial fibrillation patients. Can J Cardiol. 2015. Available from: https://doi.org/10.1016/j.cjca.2015.10.029
Farsad B, Abbasinazari M, Dabagh A, Bakshandeh H. Evaluation of Time in Therapeutic Range ( TTR ) in patients with non-valvular atrial fibrillation receiving treatment with warfarin in Tehran , Iran : A Cross-Sectional Study. 2016;20(9):20–2.
Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, et al. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting. J Electrocardiol. 2013;46(1):45–50. https://doi.org/10.1016/j.jelectrocard.2012.08.011.
Botsile E, Mwita JC. Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical heart valves: A tertiary hospital-based study in Botswana. Cardiovasc J Afr. 2020;31(4):185–9.
Jonkman LJ, Gwanyanya MP, Kakololo MN, Verbeeck RK, Singu BS. Assessment of anticoagulation management in outpatients attending a warfarin clinic in Windhoek, Namibia. Drugs Ther Perspect. 2019;35(7):341–6. https://doi.org/10.1007/s40267-019-00630-y.
Ugur A, Turk O, Tuncer E, Alioglu E, Yuksel K. Evaluation of the impact of warfarin’s time-in-therapeutic range on outcomes of patients with atrial fibrillation in Turkey : Perspectives from the Observational , Prospective WATER Registry. 2015.
Quinn LM, Richardson R, Cameron KJ, Battistella M. Evaluating time in therapeutic range for hemodialysis patients taking warfarin. Clin Nephrol. 2015;83(2):80–5.
Article CAS PubMed Google Scholar
de Castro KP, Chiu HH, De Leon-Yao RC, Almelor-Sembrana L, Dans AM. A patient decision aid for anticoagulation therapy in patients with nonvalvular atrial fibrillation: development and pilot study. JMIR Cardio. 2021;5(2):e23464.
Article PubMed PubMed Central Google Scholar
Albabtain MA, Alharthi MM, Dagriri K, Arafat AA, Ayrout E, Alhebaishi Y, et al. Assessment of the quality of anticoagulation management with warfarin in a tertiary care center. Saudi Med J. 2020;41(11):1245–51.
Article PubMed PubMed Central Google Scholar
Ouali S, Ben Halima A, Chabrak S, Chettaoui R, Ben Halima A, Haggui A, et al. Epidemiological characteristics, management, and outcomes of atrial fibrillation in TUNISIA: Results from the National Tunisian Registry of Atrial Fibrillation (NATURE-AF). Clin Cardiol. 2021;44(4):501–10 Available from: NS -.
Article PubMed PubMed Central Google Scholar
Mariita K, Nyamu DG, Maina CK, Karimi PN. Patient factors impacting on oral anticoagulation therapy among adult outpatients in a Kenyan referral hospital. 2016.
Sadhabariss D, Brown SL. Warfarin: time in therapeutic range, a single centre study on patients using warfarin for stroke prevention in non-valvular atrial fibrillation and prosthetic heart valves. SA Hear. 2021;18(1):28–38.
Tadesse TA, Tegegne GT, Yadeta D, Chelkaba L, Fenta TG. Anticoagulation control, outcomes, and associated factors in long-term-care patients receiving warfarin in Africa: a systematic review. Thromb J. 2022;20(1):1–12 10.1186/s12959-022-00416-9. https://doi.org/10.1186/s12959-022-00416-9
Fenta TG, Assefa T, Alemayehu B. Quality of anticoagulation management with warfarin among outpatients in a tertiary hospital in Addis Ababa, Ethiopia: a retrospective cross-sectional study. BMC Health Serv Res. 2017;17(1):1–7.
Yimer NS, Abiye AA, Hussen SU, Tadesse TA. Anticoagulation control, outcomes, and associated factors in patients with atrial fibrillation receiving warfarin at tertiary care hospital in Ethiopia. Clin Appl Thromb. 2021;27:107602962110497.
Liyew Z, Tadesse A, Bekele N, Tsegaye T. Evaluation of anticoagulation outcome among patients taking warfarin : a single-center experience , Northwest Ethiopia. Res Sq. 2017;20–5.
Masresha N, Muche EA, Atnafu A, Abdela O. Evaluation of warfarin anticoagulation at university of gondar comprehensive specialized hospital, north-west Ethiopia. J Blood Med. 2021;12:189–95.
Article PubMed PubMed Central Google Scholar
Getachew R, Tadesse TA, Shashu BA, Degu A, Alemkere G. Anticoagulation management in patients receiving warfarin at private cardiac centers in Addis Ababa. Ethiopia J Blood Med. 2023;14:107–17.
Article CAS PubMed Google Scholar
Teklay G, Shiferaw N, Legesse B, Bekele ML. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy : a prospective observational study. Thromb J. 2014;12(1):1–8.
Tadesse TA, Woldu MA. Prevalence of warfarin drug interaction and warfarin education practice in outpatient setups of university teaching hospital. 2018. p. 262–6.
Bungard TJ, Gardner L, Archer SL, Hamilton P, Ritchie B, Tymchak W, et al. Evaluation of a pharmacist-managed anticoagulation clinic: Improving patient care. Open Med. 2009;3(1):16–21.
Tsuyuki RT, Bungard T, Grant CM, Ackman ML. Anticoagulation clinics in North America: Operational insights. Can J Hosp Pharm. 2008;61(4):245–6.
Hou K, Yang H, Ye Z, Wang Y, Liu L, Cui X. Effectiveness of pharmacist-led anticoagulation management on clinical outcomes : a systematic review and meta-analysis. J Pharm Pharm Sci. 2017;20(1):378–96.
Shah KJ, Pharm D, Mansukhani R, Pharm D, Bloomstein D, Pharm D, et al. Outcomes of a pharmacist managed anticoagulation service. J Oncol Pharm Pract. 2010;6:62–7.
留言 (0)